Pregabalin controlled-release - Pfizer

Drug Profile

Pregabalin controlled-release - Pfizer

Alternative Names: GRO 12 - Pfizer; Lyrica CR; MR-1- Pfizer; MR-2- Pfizer; Pregabalin CR; Pregabalin ER

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Neuropathic pain; Postherpetic neuralgia
  • Phase III Fibromyalgia
  • No development reported Epilepsy

Most Recent Events

  • 31 Oct 2017 Pfizer expects launch of Pregabalin controlled release for Neuropathic pain associated with diabetic peripheral neuropathy in USA in January 2018
  • 12 Oct 2017 Registered for Neuropathic pain and Postherpetic neuralgia in USA (PO)
  • 12 Oct 2017 Updated efficacy and safety data from a phase III trial in Postherpetic neuralgia released by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top